Collegium Pharmaceutical, Inc. (COLL)

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

As of November 3, 2026, Collegium Pharmaceutical, Inc. (COLL) stock rose to $23.88, up 0.84% (+$0.20) versus the previous close. On the day, shares have traded between $23.49 and $23.92. That puts COLL near the bottom of its 52-week range of $21.43 to $50.79. Collegium Pharmaceutical, Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $774.82 million, with about 146.0K shares changing hands.

Latest COLL news

• Octave Specialty Group (OSG): A Counterintuitive Detractor Despite Strong FundamentalsYahoo Finance· Nov 2, 9:11 AM ETOSG
• Collegium Pharmaceutical (COLL) Repositioning: Shifting Focus from Pain Management to ADHDYahoo Finance· Nov 2, 9:08 AM ET
• Robert Half (RHI) Surges on Temporary Staffing Stabilization and Easing AI FearsYahoo Finance· Nov 2, 9:06 AM ETRHI
• Higher Energy Prices and Shortage Fears Drive Tidewater’s (TDW) MomentumYahoo Finance· Nov 2, 9:02 AM ETTDW
• Qualys (QLYS) Surges Following Launch of AI-Driven Vulnerability PlatformYahoo Finance· Nov 2, 9:00 AM ETQLYS
• What’s Driving PBF Energy’s (PBF) Cash Surge?Yahoo Finance· Nov 2, 8:56 AM ETPBF
• Operating Leverage and Financial Strength Anchor Champion Homes (SKY) Investment ThesisYahoo Finance· Oct 30, 12:29 PM ETSKY
• Versigent (VGNT) is Unlocking Value Through Independent Growth and Capital AllocationYahoo Finance· Oct 30, 12:17 PM ETVGNT

Source: Yahoo Finance RSS · Updated November 3, 2026

Want COLL headlines, alerts and AI research in one place? Create a free account →

• $COLL Collegium, an ADHD and pain drug maker, paid Grünenthal $17M on Oct 15 to end its 2015 Nucynta license and a patent suit over its Nucynta ER authorized generic; no further royalties are due. That's ~13% of $129.5M cash at June 30, 2026 and ~2.3% of a ~$749M market va…

  @filecrux· Oct 19, 4:18 PM ET

• $COLL saw PR, no generic competition at this point. Stock likely a long term winner

  @Stockpsych11· Oct 15, 11:12 AM ET

• $COLL been monitoring, are we losing brand exclusivity of Belbuca in 2027.

  @Stockpsych11· Oct 14, 4:14 PM ET

• Got Opium ? (non-addictive pain medicine) $COLL COLLEGIUM PHARMA. these moral victories of selling on the slightest up mini peak and buying them back cheaper, doesn't exactly pay the bills. Additionally, $SPY as of today 10/1, is on track for the worst week since August 20…

  @jewell69· Oct 1, 2:09 PM ET

• $COLL Intrinsic value bearish case potential is over 100%+ and the bullish case potential is 350%+ (source = alphaspread) 💸

  @TheLearnerEarner· Sep 29, 6:32 AM ET· Bullish

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →